3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
Lancet Psychiatry – May 01, 2018
Source: PubMed
Summary
Many military veterans and first responders struggling with severe PTSD experienced significant relief. A clinical trial investigated whether MDMA, alongside psychotherapy, could effectively treat this condition. Participants, including veterans, firefighters, and police officers, were randomly assigned different doses of MDMA or a placebo during therapy. The findings revealed substantial and lasting reductions in PTSD symptoms, with higher doses often leading to greater improvement. This innovative therapeutic approach offers a promising treatment option for individuals with profound trauma.
Abstract
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.